Trial Profile
Expanded Access Program (EAP) for Avapritinib
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Avapritinib (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions; Expanded access
- Sponsors Blueprint Medicines
- 16 Nov 2022 Status changed from completed to recruiting.
- 05 Oct 2021 Status changed from recruiting to completed.
- 10 Dec 2017 According to the American Society of Hematology media release, data from this study were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.